Risk factors

EyePoint (EYPT) risk factors

Item 1A of every EyePoint, Inc. 10-K on file, and what changed from one year to the next.

Open EYPT in Gloomberb →
  • FY2025 10-K risk factors

    61 risks, 3 new, 9 dropped, 18 reworded since the prior year. EyePoint disclosed an agreement in principle to settle a DOJ investigation regarding DEXYCU marketing for $4.7 million plus interest. Competition from better-funded rivals threatens DURAVYU and other commercial products. Manufacturing for YUTIQ remains concentrated in Watertown, Massachusetts.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors

    67 risks. Capital needs and operating losses dominate the risk section, driven by heavy R&D for the lead product candidate DURAVYU. Regulatory scrutiny, compliance with healthcare laws, and potential patent challenges pose significant threats.

    Filed Mar 06, 2025